All In Biotech

Drug Trial Radar · NCT00066690

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,066 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,066

Actual

Start

Dec 17, 2003

Primary completion

May 2014

Study completion Nov 6, 2024

Sponsor

Lead sponsor
ETOP IBCSG Partners FoundationResearch network
Sponsor type
Research network
Collaborators
Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NSABP Foundation Inc; NCIC Clinical Trials Group; North Central Cancer Treatment Group; SWOG Cancer Research Network
First posted
Aug 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

Conditions

  • Estrogen Receptor Positive Breast Cancer
  • Progesterone Receptor Positive Tumor
  • Recurrent Breast Carcinoma
  • Stage IA Breast Cancer
  • Stage IB Breast Cancer
  • Stage IIA Breast Cancer
  • Stage IIB Breast Cancer
  • Stage IIIA Breast Cancer

Interventions

  • ExemestaneDrug

    Exemestane 25mg orally daily for 5 years plus ovarian function suppression

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • OophorectomyProcedure

    Undergo bilateral surgical oophorectomy

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Radiation TherapyRadiation

    Undergo ovarian irradiation

  • TamoxifenDrug

    Tamoxifen 20mg orally daily for 5 years

  • TriptorelinDrug

    3.75 mg by im injection q28 days for 5 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free SurvivalTime frame: 5-year estimates, reported at a median follow-up of 67 months.

Locations

500 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills - Peninsula Hospitals

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Kaiser Permanente-Fremont

    Fremont, California

  • Valley Medical Oncology Consultants-Fremont

    Fremont, California

  • Glendale Memorial Hospital and Health Center

    Glendale, California

  • Marin General Hospital

    Greenbrae, California

  • Scripps Cancer Center

    La Jolla, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Bay Area Tumor Institute

    Oakland, California

  • Hematology and Oncology Associates-Oakland

    Oakland, California

  • Tom K Lee Inc

    Oakland, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Valley Medical Oncology Consultants

    Pleasanton, California

  • Eisenhower Medical Center

    Rancho Mirage, California

  • Mercy Regional Cancer Center

    Redding, California

  • Kaiser Permanente-Redwood City

    Redwood City, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Mercy General Hospital

    Sacramento, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Kaiser Permanente - Sacramento

    Sacramento, California

  • Salinas Valley Memorial

    Salinas, California

  • University of California San Diego

    San Diego, California

  • Kaiser Permanente-San Diego Mission

    San Diego, California

  • Veterans Administration-San Diego Medical Center

    San Diego, California

  • San Francisco General Hospital

    San Francisco, California

Showing 40 of 500 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.